THX Pharma Announces Financial Publication Schedule for 2026
The biopharmaceutical company THX Pharma announced on Monday its financial communication agenda for the year 2026. The company noted that announcements will be made after the closure of the Euronext Paris markets, unless otherwise stated.
Scheduled Financial Disclosures
According to the press release, the group will release its first piece of information on February 19, 2026, with the publication of its cash position as of December 31, 2025. The annual financial results for 2025 and the cash position as of March 31, 2026, will be published on April 28, 2026. The general meeting of shareholders is scheduled for June 23, 2026, at 10 AM, the company indicates. The cash position as of June 30, 2026, will be made public on July 9, 2026, while the semi-annual results as of June 30, 2026, are scheduled for September 29, 2026. Finally, the cash position as of September 30, 2026, will conclude this agenda on October 22, 2026.
Provisional Dates
THX Pharma specifies that these dates are provided for informational purposes and may be subject to change if necessary. This standard caveat allows the company to adjust its schedule according to operational or regulatory constraints. The company, commercially known as Theranexus, is listed on the Euronext Growth market in Paris.
Company Focus and Product Pipeline
According to the press release, THX Pharma positions itself as a pharmaceutical company dedicated to the treatment of rare neurological diseases. The group indicates that its first drug, TX01, will soon be marketed in Europe by Exeltis, as well as in the United States, Canada, and Australia, for Niemann-Pick disease type C and Gaucher disease. Its second product, Batten-1, targets the juvenile form of Batten disease. The company also mentions having developed an antisense oligonucleotide platform with laboratories specializing in rare neurological diseases.
